Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UBS Lifts JD HEALTH (06618.HK) TP to $85 on Strong Rev. Growth Momentum/ Continuous Margin Uptrend
Recommend 7 Positive 5 Negative 4 |
||||
|
||||
|
JD HEALTH (06618.HK)'s 3Q25 revenue and profit beat expectations, with revenue YoY growth accelerating from 24.5% in 1H25 to 28.7% in 3Q25, according to UBS' research report. UBS believed that this is mainly due to the strong growth in drug sales, a significant pick up in the health supplement business and a relatively low base in 3Q24. UBS raised its 2025-2027 earnings forecasts for JD HEALTH by 4-13%, and lifted its target price from $78.5 to $85, based on a 30x FY2027 PE ratio or adjusted earnings. The new target price implies a 1.25x PE growth rate for 2027, with rating kept at Buy. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
